Pyridine

Pyridine

SCHEMBL313836

CCCCCCCCCCCCCCCCCCCl.c1ccncc1

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.59
ALDH1A1 P00352 1/20 0.59
TDP1 Q9NUW8 3/20 0.43
NAPRT Q6XQN6 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
CASP2 P42575 1/20 0.39
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
RAD52 P43351 2/20 0.38
HSPD1 P10809 1/20 0.38
HSPE1 P61604 1/20 0.38
THRB P10828 1/20 0.36
HSP90AA1 P07900 2/20 0.35
PLA2G1B P04054 1/20 0.35
ATG4B Q9Y4P1 1/20 0.35
ABCB11 O95342 1/20 0.35
ESR1 P03372 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyridine SCHEMBL8508947 1.00 TSHR (0.59) TSHRALDH1A1TDP1NAPRTSMN1; SMN2
Pyridine SCHEMBL1258383 1.00 TSHR (0.59) TSHRALDH1A1TDP1NAPRTSMN1; SMN2
Pyridine SCHEMBL43361 1.00 TSHR (0.59) TSHRALDH1A1TDP1NAPRTSMN1; SMN2
Pyridine SCHEMBL160900 1.00 TSHR (0.59) TSHRALDH1A1TDP1NAPRTSMN1; SMN2
Pyridine SCHEMBL1389613 1.00 TSHR (0.59) TSHRALDH1A1TDP1NAPRTSMN1; SMN2
Pyridine SCHEMBL2762938 1.00 TSHR (0.59) TSHRALDH1A1TDP1NAPRTSMN1; SMN2
Pyridine SCHEMBL3912001 1.00 TSHR (0.59) TSHRALDH1A1TDP1NAPRTSMN1; SMN2
Pyridine SCHEMBL7142445 1.00 TSHR (0.59) TSHRALDH1A1TDP1NAPRTSMN1; SMN2
Pyridine SCHEMBL21641467 1.00 TSHR (0.59) TSHRALDH1A1TDP1NAPRTSMN1; SMN2
Pyridine SCHEMBL11233102 1.00 TSHR (0.59) TSHRALDH1A1TDP1NAPRTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 376 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110113942-A Synergistic antimicrobial compositions 朱比兰特生命科学有限公司 2019-08-09 CN claimed
CN-103992426-B A kind of antibacterial high water-absorbent resin and preparation method thereof 浙江卫星石化股份有限公司 2017-03-29 CN claimed
CN-105744836-A ANTI-DANDRUFF COMPOSITIONS AND HAIR CARE FORMULATIONS CONTAINING ZINC PYRITHIONE AND QUATERNARY AMMONIUM SALT 吉友联生命科学有限公司 2016-07-06 CN claimed
CN-104818002-A Filtrate reducer for palm oil, and preparation method thereof UNIV CHINA PETROLEUM 2015-08-05 CN claimed
WO-2001051767-A2 ADDITION OF SOLIDS TO GENERATE VISCOSITY DOWNHOLE SCHLUMBERGER TECHNOLOGY CORPORATION (US) 2001-07-19 WO claimed
EP-0600659-B1 Toner and developer compositions with pyridinium compounds and tetrasubstituted ammonium salts as charge enhancing additives XEROX CORP (US) 1997-07-30 EP claimed
EP-0600659-A1 Toner and developer compositions with pyridinium compounds and tetrasubstituted ammonium salts as charge enhancing additives XEROX CORPORATION (US) 1994-06-08 EP claimed
US-5304449-A Toner and developer compositions with pyridinium compounds and tetrasubstituted ammonium salts as charge enhancing additives XEROX CORPORATION (US) 1994-04-19 US claimed
EP-0278846-B1 COSMETIC COMPOSITION IN SPRAY OR AEROSOL FORM FOR THE CARE, TREATMENT AND AESTHETICS OF THE HAIR LABORATOIRE LACHARTRE SOCIETE ANONYME: (FR) 1992-04-15 EP claimed
EP-0004953-B1 PROCESS AND APPARATUS FOR THE SELECTIVE SEPARATION OF URANIUM FROM ITS ACCOMPANYING METALS AND FOR ITS RECOVERY Heckmann, Klaus, Prof. Dr. (DE) 1982-03-03 EP claimed
US-20260042956-A1 METHOD FOR SINGLE-STAGE TREATMENT OF SILICEOUS SUBTERRANEAN FORMATIONS SCHLUMBERGER TECHNOLOGY CORPORATION 2026-02-12 US disclosed
CN-110880552-B Perovskite solution and surfactant step-by-step coating equipment and method thereof 杭州纤纳光电科技有限公司 2024-10-18 CN disclosed
WO-2024141403-A1 ANHYDROUS CLEANSING COMPOSITION UNILEVER IP HOLDINGS B.V. (NL) 2024-07-04 WO disclosed
WO-2024141375-A1 TRANSLUCENT OR TRANSPARENT ISOTROPIC LIQUID WASH COMPOSITION UNILEVER IP HOLDINGS B.V. (NL) 2024-07-04 WO disclosed
WO-2024141377-A1 ISOTROPIC LIQUID WASH COMPOSITION WITH ESTERIFIED NONIONIC THICKENER UNILEVER IP HOLDINGS B.V. (NL) 2024-07-04 WO disclosed
US-4264697-A TONER RESIN, COLORANT, AND A CHARGE INDUCTING HYDRAZINIUM OR PYRIDINIUM COMPOUND XEROX CORPORATION (US) 1981-04-28 US disclosed
EP-0022347-A1 Electrostatographic developer mixture XEROX CORPORATION (US) 1981-01-14 EP disclosed
EP-0005952-A1 Electrostatographic toner containing an alkyl pyridinium compound and imaging method XEROX CORPORATION (US) 1979-12-12 EP disclosed
US-4156887-A PYRIDINE, QUINOLINE OR 1,10-PHENANTHROLINE COMPOUND HAVING REVERSIBLE PHASE TRANSITION COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 1979-05-29 US disclosed
US-4041205-A SURFACTANTS AND A REINFORCEMENT SELECTED FROM CELLULOSE, PROTEIN, AND NYLON COLGATE-PALMOLIVE COMPANY (US) 1977-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042956-A1 METHOD FOR SINGLE-STAGE TREATMENT OF SILICEOUS SUBTERRANEAN FORMATIONS YAP1, S100A10, FOXM1 TSHR 2378/4885ALDH1A1 4656/4885TDP1 3039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.